[Editorial] UKCTOCS and the evaluation of screening for ovarian cancer
Ovarian cancer is the fifth most common cause of cancer-related death in women in Europe. Vague symptoms mean that most women present with advanced disease, so that 5-year survival is less than 40%. Progress in the past generation has been slow, with little added benefit from biomarkers, mechanism-based treatments, or surgical innovations. Recently, emphasis has shifted to earlier diagnosis with clinical decision aids and population screening—a challenging proposition for a disease of low prevalence and without a recognisable latent phase.